315 related articles for article (PubMed ID: 21508392)
1. PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations.
Panebianco V; Sciarra A; De Berardinis E; Busetto GM; Lisi D; Buonocore V; Gentile V; Di Silverio F; Passariello R
Anticancer Res; 2011 Apr; 31(4):1399-405. PubMed ID: 21508392
[TBL] [Abstract][Full Text] [Related]
2. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy.
Sciarra A; Panebianco V; Ciccariello M; Salciccia S; Cattarino S; Lisi D; Gentilucci A; Alfarone A; Bernardo S; Passariello R; Gentile V
Clin Cancer Res; 2010 Mar; 16(6):1875-83. PubMed ID: 20197480
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
4. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.
Kumar V; Jagannathan NR; Kumar R; Thulkar S; Gupta SD; Hemal AK; Gupta NP
NMR Biomed; 2007 Feb; 20(1):11-20. PubMed ID: 16894640
[TBL] [Abstract][Full Text] [Related]
5. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
[TBL] [Abstract][Full Text] [Related]
6. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer.
Sciarra A; Panebianco V; Salciccia S; Osimani M; Lisi D; Ciccariello M; Passariello R; Di Silverio F; Gentile V
Eur Urol; 2008 Sep; 54(3):589-600. PubMed ID: 18226441
[TBL] [Abstract][Full Text] [Related]
7. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
[TBL] [Abstract][Full Text] [Related]
8. Role of magnetic resonance spectroscopic imaging ([¹H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA).
Panebianco V; Sciarra A; Ciccariello M; Lisi D; Bernardo S; Cattarino S; Gentile V; Passariello R
Radiol Med; 2010 Dec; 115(8):1314-29. PubMed ID: 20852963
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of MRI/MRSI for patients with persistently high PSA levels and negative TRUS-guided biopsy results.
Bhatia C; Phongkitkarun S; Booranapitaksonti D; Kochakarn W; Chaleumsanyakorn P
J Med Assoc Thai; 2007 Jul; 90(7):1391-9. PubMed ID: 17710982
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
[TBL] [Abstract][Full Text] [Related]
11. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
12. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
[TBL] [Abstract][Full Text] [Related]
13. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy.
Yuen JS; Thng CH; Tan PH; Khin LW; Phee SJ; Xiao D; Lau WK; Ng WS; Cheng CW
J Urol; 2004 Apr; 171(4):1482-6. PubMed ID: 15017203
[TBL] [Abstract][Full Text] [Related]
14. uPM3, a new molecular urine test for the detection of prostate cancer.
Fradet Y; Saad F; Aprikian A; Dessureault J; Elhilali M; Trudel C; Mâsse B; Piché L; Chypre C
Urology; 2004 Aug; 64(2):311-5; discussion 315-6. PubMed ID: 15302485
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL.
Okcelik S; Soydan H; Ates F; Berber U; Saygin H; Sonmez G; Karademir K
Int Braz J Urol; 2016; 42(3):449-55. PubMed ID: 27286106
[TBL] [Abstract][Full Text] [Related]
16. Reflex PCA3 messenger ribonucleic acid testing: validation of postbiopsy urine samples and correlation with prostate biopsy findings in ∼2000 patients.
Brown JG; Fulmer JR; Romano J; Pownell J; Rigler W; Wirtshafter A; Sarno M; Shappell SB
Urology; 2014 Nov; 84(5):1172-80. PubMed ID: 25443926
[TBL] [Abstract][Full Text] [Related]
17. Localising prostate cancer: comparison of endorectal magnetic resonance (MR) imaging and 3D-MR spectroscopic imaging with transrectal ultrasound-guided biopsy.
Goris Gbenou MC; Peltier A; Addla SK; Lemort M; Bollens R; Larsimont D; Roumeguère T; Schulman CC; van Velthoven R
Urol Int; 2012; 88(1):12-7. PubMed ID: 22004874
[TBL] [Abstract][Full Text] [Related]
18. Molecular PCA3 diagnostics on prostatic fluid.
van Gils MP; Cornel EB; Hessels D; Peelen WP; Witjes JA; Mulders PF; Rittenhouse HG; Schalken JA
Prostate; 2007 Jun; 67(8):881-7. PubMed ID: 17440939
[TBL] [Abstract][Full Text] [Related]
19. [Does PCA3 score and prostatic MRI help selection of patients scheduled for initial prostatic biopsy?].
Vinet M; Vlaeminck-Guillem V; Rouvière O; Perrin P; Paparel P; Devonec M; Adam E; Briant PE; Ruffion A
Prog Urol; 2013 Feb; 23(2):121-7. PubMed ID: 23352305
[TBL] [Abstract][Full Text] [Related]
20. [Outcomes of expanded use of PCA3 testing in a Spanish population with clinical suspicion of prostate cancer].
Rubio-Briones J; Fernández-Serra A; Ramírez M; Rubio L; Collado A; Casanova J; Gómez-Ferrer A; Ricós JV; Monrós JL; Dumont R; Ortiz B; Iborra I; García-Casado Z; Solsona E; López-Guerrero JA
Actas Urol Esp; 2011; 35(10):589-96. PubMed ID: 21700365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
